Lenalidomide, Bortezomib, and Dexamethasone with Transplantation in Myeloma.

BACKGROUND: High-dose chemotherapy with autologous stem cell transplantation has been the standard treatment for young patients with newly diagnosed myeloma. However, promising emerging data with the combination of lenalidomide, bortezomib and dexamethasone (RVD) have raised questions about the role...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:N Engl J Med
Päätekijät: Attal, Michel, Lauwers-Cances, Valerie, Hulin, Cyrille, Leleu, Xavier, Caillot, Denis, Escoffre, Martine, Arnulf, Bertrand, Macro, Margaret, Belhadj, Karim, Garderet, Laurent, Roussel, Murielle, Payen, Catherine, Mathiot, Claire, Fermand, Jean Paul, Meuleman, Nathalie, Rollet, Sandrine, Maglio, Michelle E., Zeytoonjian, Andrea A., Weller, Edie A., Munshi, Nikhil, Anderson, Kenneth C., Richardson, Paul G., Facon, Thierry, Avet-Loiseau, Hervé, Harousseau, Jean-Luc, Moreau, Philippe
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201242/
https://ncbi.nlm.nih.gov/pubmed/28379796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1611750
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia